{"id":"W2805592007","doi":"10.1016/s1470-2045(18)30351-6","title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2536,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Adverse effect; Response Evaluation Criteria in Solid Tumors; Population; Oncology; Discontinuation; Clinical trial; Phases of clinical research; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001511291,0.00139486,0.002334464,0.0003159672,0.0003243759,0.001114314,0.0004754582,0.001185065,0.004731635],"category_scores_gemma":[0.001308879,0.0005465918,0.002060571,0.0003549094,0.0008036386,0.001359865,0.0004064382,0.002678124,0.000948113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00072993,"about_ca_system_score_gemma":0.0007644733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008567562,"about_ca_topic_score_gemma":0.00177596,"domain_scores_codex":[0.9995603,0.0002249336,0.00002377635,0.00007346441,0.00002757068,0.00008988533],"domain_scores_gemma":[0.9994732,0.0001330187,0.0001214209,0.0000416205,0.0000286779,0.0002021243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9538386,0.004447645,0.001685023,0.0009179621,0.001966775,0.00008088331,0.00007590077,0.0007010108,0.003433473,0.0001478536,0.001385393,0.0313194],"study_design_scores_gemma":[0.9233016,0.06913009,0.004327935,0.00005568074,0.0008719969,0.00008503078,0.00004201143,0.0004715607,0.0004260052,0.0002279034,0.001039505,0.00002079215],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891185,0.005578705,0.0004031599,0.001074448,0.0004009969,0.0009968645,0.0007138883,0.00008079356,0.001632569],"genre_scores_gemma":[0.9902804,0.003511319,0.0006454292,0.0008940428,0.0002663889,0.001089927,0.001193667,0.00001531314,0.002103418],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004731635,"threshold_uncertainty_score":0.01582885,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07727556601902094,"score_gpt":0.3280706321942589,"score_spread":0.2507950661752379,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}